ClinicalTrials.gg
CompletedNCT06825416Updated Aug 28, 2026

A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

A Phase 3 interventional study of SHR-2004 injection and SHR-2004 injection in Prevention of Arterial and Venous Thrombosis, sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Completed at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,165
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Venous Thrombosis with a site in China — 16 open to participants now, 18 under way, 2 of them phase 3. Venous Thrombosis · China.

Enrollment
12th of 41
1,165 · median 360
Started
2025
with 4 others
Phase 3
16 of 59
1 open now
Registered
50th of 59
by date
Lead sponsor
2 of 59
Beijing Suncadia Pharmaceuticals Co., Ltd

Among the 59 studies in Venous Thrombosis with a site in China, this one is the 12th largest by enrollment of the 41 interventional ones that give a count, is one of 5 that started in 2025, is one of 16 in phase 3, and was the 50th registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

16 of the 59 studies in Venous Thrombosis with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Venous Thrombosis with a site in China, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy and safety of SHR-2004 in preventing venous thromboembolism after elective unilateral total knee arthroplasty.

03

Conditions studied

  • Prevention of Arterial and Venous Thrombosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understand the research procedures and methods, volunteer to participate in this trial, and sign the form in writing;
  2. Planned elective schedule total knee arthroplasty (TKA) patients;
  3. Men or women who are ≥ 18 years old and \< 80 years old on the day of signing the informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Unable to receive CT angiography of both lower limbs;
  2. Malignant tumor within one year of the screening;
  3. Myocardial infarction, or ischemic stroke occurred within 6 months of the screening;
  4. Any medical history that may increase the risk of bleeding or any conditions that the investigator considers to increase the risk of bleeding;
  5. History of drug abuse;
  6. Pregnant or lactating women.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,165 participants (actual)

Study arms

  • Experimental
    Group A

    Drug: SHR-2004 injection · Drug: Enoxaparin sodium injection placebo · Drug: SHR-2004 placebo

  • Experimental
    Group B

    Drug: SHR-2004 injection · Drug: Enoxaparin sodium injection placebo · Drug: SHR-2004 placebo

  • Active comparator
    Group C

    Drug: Enoxaparin sodium injection · Drug: SHR-2004 placebo

Interventions

  • SHR-2004 injection in low dose.

  • SHR-2004 injection in high dose.

  • Enoxaparin sodium injection.

  • DrugEnoxaparin sodium injection placebo

    Enoxaparin sodium injection placebo.

  • DrugSHR-2004 placebo

    SHR-2004 placebo in low dose.

  • DrugSHR-2004 placebo

    SHR-2004 placebo in high dose.

06

What researchers measure

Primary outcomes

  1. Incidence of asymptomatic deep vein thrombosis (DVT)

    Time frame: Day 12.

  2. Incidence of non-fatal pulmonary embolism (PE)

    Time frame: Day 12.

Secondary outcomes

  1. Adverse events (AEs)

    Time frame: Day 65.

  2. Bleeding events

    Time frame: Day 12.

07

Study locations

2 sites
  • Fourth Medical Center of Chinese People's Liberation Army General Hospital
    Beijing, Beijing Municipality 100048, China
  • Xiangya Hospital, Central South University
    Changsha, Hunan 410008, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Feb 2026, 10 months.

Of 34 phase 3 interventional studies under Venous Thrombosis, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 58. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2025
First posted
Feb 13, 2025
StartActual
Mar 16, 2025
Primary completionActual
Feb 15, 2026
CompletionActual
Apr 23, 2026
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06825416
Responsible party
Sponsor
First posted
Feb 13, 2025
Start date
Mar 16, 2025
Primary completion
Feb 15, 2026
Completion
Apr 23, 2026
Last update
Aug 28, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-2004

Start the discussion